Showing results (231-240 of 302) with videos related to
Sort By:
Pageof 31
Frontiers in Immunology|February 8, 2021
Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary ComplicationsSang T Kim, Ajay Sheshadri, Vickie Shannon, et al.Journal of Cancer Research and Clinical Oncology|July 5, 2024
Gastrointestinal toxicities of proteasome inhibitor therapyJay Shah, Samanthika Devalaraju, Elliot Baerman, et al.Nature Cancer|January 6, 2026
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trialPaolo Strati, Lori Leslie, Parveen Shiraz, et al.Blood|September 21, 2019
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapyPhilip A Thompson, Jaya Srivastava, Christine Peterson, et al.British Journal of Haematology|December 17, 2016
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.Blood Advances|November 14, 2022
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCLHua-Jay J Cherng, Stefan K Alig, Yasuhiro Oki, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2011
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphomaStephen J Schuster, Sattva S Neelapu, Barry L Gause, et al.Blood Cancer Journal|May 6, 2020
Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-upHui Zhou, Zijun Y Xu-Monette, Ling Xiao, et al.Haematologica|June 20, 2015
Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experiencePaolo Strati, Samih H Nasr, Nelson Leung, et al.The Lancet. Oncology|June 9, 2012
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialMichael Wang, Luis Fayad, Nicolaus Wagner-Bartak, et al.Pageof 31